Results 201 to 210 of about 188,791 (289)

Comparative efficacy and safety of rituximab versus cyclophosphamide with steroids in primary membranous nephropathy: a systematic review and meta-analysis. [PDF]

BMC Nephrol
Huang F, Fu C, Liu M, Wu P, Li Y, Lu Z, Li Y, Xie Y.   +7 more
europepmc   +1 more source

Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

British Journal of Haematology, EarlyView.
Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin, Francesco Autore, Anna Maria Frustaci, Gianmarco Favrin, Emanuele Cencini, Alessandro Noto, Irene Dogliotti, Jacopo Olivieri, Marcello Riva, Isacco Ferrarini, Anna Maria Barbui, Sara Steffanoni, Dario Marino, Benedetta Puccini, Piero Maria Stefani, Rita Rizzi, Michele Merli, Angela Ferrari, Stefano Luminari, Carlo Visco, Livio Trentin, Andrea Visentin, Annarita Conconi, Simone Ferrero, Marzia Varettoni, Alessandra Tedeschi, Luca Laurenti, Francesco Piazza   +27 more
wiley   +1 more source

Real-world clinical effectiveness of trimethoprim-sulfamethoxazole for primary prophylaxis of pneumocystis pneumonia in non-hodgkin lymphoma patients treated with rituximab. [PDF]

PLoS One
Charoenrit P, Niparuck P, Rotjanapan P.
europepmc   +1 more source

Clinical features and comorbidity patterns in early and very early rheumatoid arthritis: Insights from a China nationwide survey

Rheumatology &Autoimmunity, EarlyView.
Haojie Xu, Liyun Zhang, Yuehong Huo, Rui Wu, Lijun Wu, Ling Lei, Linyu Geng, Chunyu Tan, Xiaomei Li, Ru Li, Yin Su, the Women's Rheumatoid Arthritis Research Collaborative Group   +11 more
wiley   +1 more source

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome

British Journal of Haematology, EarlyView.
Fostamatinib had 46% durable response, with 73% steroid reduction, in this multicentre retrospective study of refractory wAIHA/ES. Hypertension, gastrointestinal (GI) distress and neutropenia occurred in 23%. Only one patient required drug discontinuation and one patient dose reduction.
Jorge N. Ruiz Lopez, Lipei Shao, Debbie Jiang, Lawrence S. Bailey, Thejaswi Bikkani, Aaron Boothby, Donald C. Moore, Irina Murakhovskaya, Caroline I. Piatek, Mauricio Pineda‐Roman, Ping Jin, Jacqueline N. Poston, Moritz Stolla, David F. Stroncek, Krystalyn E. Hudson, James B. Bussel, Sandhya R. Panch   +16 more
wiley   +1 more source

Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab. [PDF]

Cancer
Davies GA, Prica A, Ante Z, Liu N, Pond GR, Balitsky AK, Suleman A, Mozessohn L.   +7 more
europepmc   +1 more source

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: Results for CALGB 10404 (Alliance) [PDF]

, 2018
Fehniger, Todd A.
core   +1 more source

Disseminated <i>Ureaplasma</i> infection: a case report of a patient with rheumatoid arthritis on rituximab therapy with multiple abscesses and arthritis. [PDF]

Ups J Med Sci
Sindelar L, Hall A, Eriksson G, Lennebratt D, Pauksens K.   +4 more
europepmc   +1 more source